The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback